Literature DB >> 30237235

"Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers.

Rasimcan Meral1, Benjamin J Ryan2, Noemi Malandrino3, Abdelwahab Jalal1, Adam H Neidert1, Ranganath Muniyappa3,4, Barış Akıncı5, Jeffrey F Horowitz2, Rebecca J Brown3, Elif A Oral6.   

Abstract

OBJECTIVE: Lipodystrophy syndromes are a heterogeneous group of disorders associated with selective absence of fat. Currently, the diagnosis is established only clinically. RESEARCH DESIGN AND METHODS: We developed a new method from DXA scans called a "fat shadow," which is a color-coded representation highlighting only the fat tissue. We conducted a blinded retrospective validation study to assess its usefulness for the diagnosis of lipodystrophy syndromes.
RESULTS: We evaluated the fat shadows from 16 patients (11 female and 5 male) with generalized lipodystrophy (GL), 57 (50 female and 7 male) with familial partial lipodystrophy (FPLD), 2 (1 female and 1 male) with acquired partial lipodystrophy, and 126 (90 female and 36 male) control subjects. FPLD was differentiated from control subjects with 85% sensitivity and 96% specificity (95% CIs 72-93 and 91-99, respectively). GL was differentiated from nonobese control subjects with 100% sensitivity and specificity (95% CIs 79-100 and 92-100, respectively).
CONCLUSIONS: Fat shadows provided sufficient qualitative information to infer clinical phenotype and differentiate these patients from appropriate control subjects. We propose that this method could be used to support the diagnosis.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2018        PMID: 30237235      PMCID: PMC6150431          DOI: 10.2337/dc18-0978

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  13 in total

1.  Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.

Authors:  Nevin Ajluni; Rasimcan Meral; Adam H Neidert; Graham F Brady; Eric Buras; Barbara McKenna; Frank DiPaola; Thomas L Chenevert; Jeffrey F Horowitz; Colleen Buggs-Saxton; Amit R Rupani; Peedikayil E Thomas; Marwan K Tayeh; Jeffrey W Innis; M Bishr Omary; Hari Conjeevaram; Elif A Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-27       Impact factor: 3.478

2.  Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome.

Authors:  Cristina Guillín-Amarelle; Sofía Sánchez-Iglesias; Ana Castro-Pais; Leticia Rodriguez-Cañete; Lucía Ordóñez-Mayán; Marcos Pazos; Blanca González-Méndez; Silvia Rodríguez-García; Felipe F Casanueva; Ana Fernández-Marmiesse; David Araújo-Vilar
Journal:  Endocrine       Date:  2016-07-30       Impact factor: 3.633

3.  Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.

Authors:  Elif A Oral; Shannon M Reilly; Andrew V Gomez; Rasimcan Meral; Laura Butz; Nevin Ajluni; Thomas L Chenevert; Evgenia Korytnaya; Adam H Neidert; Rita Hench; Diana Rus; Jeffrey F Horowitz; BreAnne Poirier; Peng Zhao; Kim Lehmann; Mohit Jain; Ruth Yu; Christopher Liddle; Maryam Ahmadian; Michael Downes; Ronald M Evans; Alan R Saltiel
Journal:  Cell Metab       Date:  2017-07-05       Impact factor: 27.287

Review 4.  Human lipodystrophies: genetic and acquired diseases of adipose tissue.

Authors:  Jacqueline Capeau; Jocelyne Magré; Martine Caron-Debarle; Claire Lagathu; Bénédicte Antoine; Vé Ronique Béréziat; Olivier Lascols; Jean-Philippe Bastard; Corinne Vigouroux
Journal:  Endocr Dev       Date:  2010-06-15

5.  Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance.

Authors:  Luca A Lotta; Pawan Gulati; Felix R Day; Felicity Payne; Halit Ongen; Martijn van de Bunt; Kyle J Gaulton; John D Eicher; Stephen J Sharp; Jian'an Luan; Emanuella De Lucia Rolfe; Isobel D Stewart; Eleanor Wheeler; Sara M Willems; Claire Adams; Hanieh Yaghootkar; Nita G Forouhi; Kay-Tee Khaw; Andrew D Johnson; Robert K Semple; Timothy Frayling; John R B Perry; Emmanouil Dermitzakis; Mark I McCarthy; Inês Barroso; Nicholas J Wareham; David B Savage; Claudia Langenberg; Stephen O'Rahilly; Robert A Scott
Journal:  Nat Genet       Date:  2016-11-14       Impact factor: 38.330

6.  Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation.

Authors:  Cynthia M Valerio; Lenita Zajdenverg; José Egídio P de Oliveira; Patricia B Mory; Regina S Moyses; Amélio F Godoy-Matos
Journal:  Diabetol Metab Syndr       Date:  2012-08-31       Impact factor: 3.320

7.  Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Authors:  Nevin Ajluni; Moahad Dar; John Xu; Adam H Neidert; Elif A Oral
Journal:  J Diabetes Metab       Date:  2016-03-23

Review 8.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

Review 9.  Lipodystrophy: metabolic insights from a rare disorder.

Authors:  Isabel Huang-Doran; Alison Sleigh; Justin J Rochford; Stephen O'Rahilly; David B Savage
Journal:  J Endocrinol       Date:  2010-09-24       Impact factor: 4.286

10.  Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis.

Authors:  Melis Sahinoz; Shafaq Khairi; Ashley Cuttitta; Graham F Brady; Amit Rupani; Rasimcan Meral; Marwan K Tayeh; Peedikayil Thomas; Meredith Riebschleger; Sandra Camelo-Piragua; Jeffrey W Innis; M Bishr Omary; Daniel E Michele; Elif A Oral
Journal:  Clin Diabetes Endocrinol       Date:  2018-03-27
View more
  10 in total

1.  Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.

Authors:  Baris Akinci; Angela Subauste; Nevin Ajluni; Nazanene H Esfandiari; Rasimcan Meral; Adam H Neidert; Akin Eraslan; Rita Hench; Diana Rus; Barbara McKenna; Hero K Hussain; Thomas L Chenevert; Marwan K Tayeh; Amit R Rupani; Jeffrey W Innis; Christos S Mantzoros; Hari S Conjeevaram; Charles L Burant; Elif A Oral
Journal:  Med (N Y)       Date:  2021-05-12

2.  Approach to the Patient With Lipodystrophy.

Authors:  Lindsay T Fourman; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

3.  Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.

Authors:  Chandna Vasandani; Xilong Li; Hilal Sekizkardes; Beverley Adams-Huet; Rebecca J Brown; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

4.  UNUSUAL PRESENTATIONS OF LMNA-ASSOCIATED LIPODYSTROPHY WITH COMPLEX PHENOTYPES AND GENERALIZED FAT LOSS: WHEN THE GENETIC DIAGNOSIS UNCOVERS NOVEL FEATURES.

Authors:  Natalia Xavier S de Andrade; Suleyman Cem Adiyaman; Berna Demir Yuksel; Carla T Ferrari; Abdelwahab Jalal Eldin; Basak Ozgen Saydam; Canan Altay; Pratima Sharma; Nicole Bhave; Ann Little; Paul McKeever; Huseyin Onay; Sermin Ozkal; Mustafa Secil; Mustafa Nuri Yenerel; Baris Akinci; Elif A Oral
Journal:  AACE Clin Case Rep       Date:  2020-03-04

5.  Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.

Authors:  Nazanene H Esfandiari; Melvyn Rubenfire; Adam H Neidert; Rita Hench; Abdelwahab Jalal Eldin; Rasimcan Meral; Elif A Oral
Journal:  Clin Diabetes Endocrinol       Date:  2019-03-14

Review 6.  Familial Partial Lipodystrophy (FPLD): Recent Insights.

Authors:  Christos Bagias; Angeliki Xiarchou; Alexandra Bargiota; Stelios Tigas
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-06       Impact factor: 3.168

7.  Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.

Authors:  Maria C Foss-Freitas; Baris Akinci; Adam Neidert; Victoria J Bartlett; Eunju Hurh; Ewa Karwatowska-Prokopczuk; Elif A Oral
Journal:  Lipids Health Dis       Date:  2021-12-05       Impact factor: 3.876

8.  Silhouette images enable estimation of body fat distribution and associated cardiometabolic risk.

Authors:  Marcus D R Klarqvist; Saaket Agrawal; Nathaniel Diamant; Patrick T Ellinor; Anthony Philippakis; Kenney Ng; Puneet Batra; Amit V Khera
Journal:  NPJ Digit Med       Date:  2022-07-27

9.  Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots.

Authors:  Saaket Agrawal; Minxian Wang; Marcus D R Klarqvist; Kirk Smith; Joseph Shin; Hesam Dashti; Nathaniel Diamant; Seung Hoan Choi; Sean J Jurgens; Patrick T Ellinor; Anthony Philippakis; Melina Claussnitzer; Kenney Ng; Miriam S Udler; Puneet Batra; Amit V Khera
Journal:  Nat Commun       Date:  2022-06-30       Impact factor: 17.694

10.  The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.

Authors:  Baris Akinci; Rasimcan Meral; Diana Rus; Rita Hench; Adam H Neidert; Frank DiPaola; Maria Westerhoff; Simeon I Taylor; Elif A Oral
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.